OrthoPediatrics (NASDAQ:KIDS - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.04, Zacks reports. The firm had revenue of $52.67 million for the quarter, compared to analyst estimates of $51.16 million. OrthoPediatrics had a negative return on equity of 5.78% and a negative net margin of 15.00%. During the same period in the prior year, the company earned ($0.23) EPS. OrthoPediatrics updated its FY 2025 guidance to EPS.
OrthoPediatrics Stock Up 1.0 %
Shares of NASDAQ KIDS traded up $0.24 during mid-day trading on Friday, hitting $25.35. 234,121 shares of the stock traded hands, compared to its average volume of 321,675. The company has a debt-to-equity ratio of 0.19, a quick ratio of 3.68 and a current ratio of 7.17. OrthoPediatrics has a 52 week low of $21.02 and a 52 week high of $35.99. The company has a market cap of $613.88 million, a price-to-earnings ratio of -20.61 and a beta of 1.14. The stock has a fifty day moving average price of $24.48 and a 200-day moving average price of $25.93.
Wall Street Analysts Forecast Growth
KIDS has been the topic of a number of analyst reports. Stifel Nicolaus decreased their price target on OrthoPediatrics from $40.00 to $32.00 and set a "buy" rating on the stock in a research note on Wednesday. Truist Financial decreased their price target on OrthoPediatrics from $28.00 to $25.00 and set a "hold" rating on the stock in a research note on Wednesday, December 18th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $42.00 price target on shares of OrthoPediatrics in a research note on Wednesday.
Check Out Our Latest Stock Analysis on KIDS
OrthoPediatrics Company Profile
(
Get Free Report)
OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.
Featured Articles
Before you consider OrthoPediatrics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OrthoPediatrics wasn't on the list.
While OrthoPediatrics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
